PriceTargets.com logo

Neuronetics - STIM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.67
  • Forecasted Upside: 219.63%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.46 As of 12/24/2024 06:19 PM ET
▲ +0.13 (9.77%)

This chart shows the closing price for STIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neuronetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STIM

Analyst Price Target is $4.67
▲ +219.63% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Neuronetics in the last 3 months. The average price target is $4.67, with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a 219.63% upside from the last price of $1.46.

This chart shows the closing price for STIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Neuronetics. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$7.00 ➝ $3.00
8/13/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$6.00 ➝ $3.00
8/12/2024William BlairReiterated RatingOutperform ➝ Market Perform
5/14/2024William BlairUpgradeMarket Perform ➝ Outperform
3/26/2024William BlairReiterated RatingMarket Perform
3/6/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
3/8/2023Canaccord Genuity GroupLower TargetBuy$9.00 ➝ $7.00
3/8/2023JMP SecuritiesReiterated RatingMarket Outperform$12.00
11/9/2022Canaccord Genuity GroupBoost Target$9.00 ➝ $10.00
1/3/2022Piper SandlerLower Target$10.00 ➝ $9.00
10/14/2021JMP SecuritiesReiterated RatingBuy$18.00 ➝ $12.00
10/13/2021William BlairDowngradeOutperform ➝ Market Perform
10/13/2021BTIG ResearchDowngradeBuy ➝ Neutral
8/3/2021Piper SandlerLower TargetOverweight$21.00 ➝ $12.00
3/2/2021Piper SandlerLower TargetOverweight$27.00 ➝ $25.00
1/27/2021JMP SecuritiesBoost TargetOutperform$15.00 ➝ $23.00
1/22/2021William BlairUpgradeMarket Perform ➝ Outperform
1/21/2021BTIG ResearchBoost TargetBuy$14.00 ➝ $21.00
1/21/2021Piper SandlerBoost TargetOverweight$20.00 ➝ $27.00
1/12/2021Piper SandlerBoost TargetOverweight$9.00 ➝ $20.00
1/8/2021JMP SecuritiesBoost Target$10.00 ➝ $15.00
12/7/2020BTIG ResearchBoost TargetBuy$10.00 ➝ $14.00
11/23/2020Piper SandlerBoost TargetOverweight$7.00 ➝ $9.00
10/6/2020BTIG ResearchBoost TargetBuy$6.00 ➝ $10.00
8/4/2020BTIG ResearchReiterated RatingBuy$6.00
5/5/2020William BlairDowngradeOutperform ➝ Market Perform
5/5/2020BTIG ResearchReiterated RatingBuy$6.00
4/9/2020BTIG ResearchLower Target$11.00 ➝ $6.00
3/4/2020Piper SandlerLower Target$14.00 ➝ $6.00
2/6/2020BTIG ResearchInitiated CoverageBuy$11.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Neuronetics logo
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.46
Low: $1.25
High: $1.48

50 Day Range

MA: $1.06
Low: $0.61
High: $1.46

52 Week Range

Now: $1.46
Low: $0.52
High: $5.07

Volume

198,257 shs

Average Volume

293,222 shs

Market Capitalization

$44.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Neuronetics?

The following equities research analysts have issued research reports on Neuronetics in the last year: Canaccord Genuity Group Inc., JMP Securities, Piper Sandler, and William Blair.
View the latest analyst ratings for STIM.

What is the current price target for Neuronetics?

0 Wall Street analysts have set twelve-month price targets for Neuronetics in the last year. Their average twelve-month price target is $4.67, suggesting a possible upside of 219.6%. Piper Sandler has the highest price target set, predicting STIM will reach $8.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $3.00 for Neuronetics in the next year.
View the latest price targets for STIM.

What is the current consensus analyst rating for Neuronetics?

Neuronetics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for STIM.

What other companies compete with Neuronetics?

Other companies that are similar to Neuronetics include Pro-Dex, Nevro, Jin Medical International, TriSalus Life Sciences and electroCore. Learn More about companies similar to Neuronetics.

How do I contact Neuronetics' investor relations team?

Neuronetics' physical mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company's listed phone number is (610) 640-4202 and its investor relations email address is [email protected]. The official website for Neuronetics is www.neurostar.com. Learn More about contacing Neuronetics investor relations.